The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Murray, H. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, H. W.
The Journal of Immunology, 2005, 174: 4916-4923.
Copyright © 2005 by The American Association of Immunologists

Prevention of Relapse after Chemotherapy in a Chronic Intracellular Infection: Mechanisms in Experimental Visceral Leishmaniasis1

Henry W. Murray2

Department of Medicine, Weill Medical College of Cornell University, New York, NY 10021


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
In visceral leishmaniasis, chemotherapy probably seldom eradicates all parasites in tissue macrophages; nevertheless, most T cell-intact patients show long-lasting clinical cure after treatment despite residual intracellular infection. To characterize prevention of posttreatment relapse, amphotericin B was used to kill ~90–95% of Leishmania donovani in livers of mice deficient in mechanisms of acquired antileishmanial resistance. Recrudescence subsequently developed 1) in animals deficient in both CD4 and CD8 T cells as well as CD40L-mediated T cell costimulation, but not in a) CD4 or CD8 cells alone, b) NK cell lytic activity, or c) ICAM-1-recruited monocytes; and 2) in mice deficient in IFN-{gamma}, but not in the IFN-{gamma}-inducing cytokines, a) IL-12, b) IL-12 and IL-23, or c) IL-18. Posttreatment recrudescence also did not develop in animals deficient in macrophage phagocyte NADPH oxidase (phox) or inducible NO synthase (iNOS) alone or, surprisingly, in those deficient in both phox and iNOS. Therefore, regulation of the intracellular replication of residual Leishmania donovani that escape chemotherapy evolves to a host mechanism distinguishable from initial acquired resistance at the T cell, cytokine, and macrophage levels. Posttreatment, either CD8 or CD4 cells can direct the response, IL-12 is not required, and iNOS and phox, the activated macrophage’s primary IFN-{gamma}-inducible leishmanicidal pathways, both become dispensable.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 Disclosures
 References
 
Visceral leishmaniasis (kala-azar) is a disseminated intracellular protozoal infection that targets tissue macrophages in the liver, spleen, and bone marrow. In otherwise immunocompetent patients who develop fully expressed disease, treatment with pentavalent antimony (Sb), 3 amphotericin B (AmB), or miltefosine induces initial clinical and parasitologic responses in >90% of cases (1, 2). 4 However, relapse after an apparent response to any drug regimen is well recognized in kala-azar, even in phenotypically normal individuals. The risk of recurrence is highest in the first 6–12 mo after therapy (1, 2, 3, 4, 5); thus, treated patients are not considered complete clinical responders (definitive cures) until at least 6 posttreatment months have passed uneventfully (6).

However, neither chemotherapy (nor a satisfactorily expressed T cell-dependent host immune response (1)) is thought to eradicate all tissue parasites in any form of leishmaniasis (7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18). In successfully treated kala-azar, for example, visceral macrophages are presumed to harbor quiescent parasites, probably for life. A similar state of chronic intracellular parasitism apparently exists in a considerably larger population as well, individuals also infected with visceralizing Leishmania species, but without expression of clinical illness (2, 19, 20). In either setting, T cell-dependent effects along with cytokine-regulated macrophage activation probably maintain treated and subclinical infection in the latent state (1, 2, 9, 10, 11, 12, 13, 14, 16, 18, 20, 21, 22, 23, 24). Although residual tissue parasites presumably provide ongoing immunization important in resistance to reinfection (18, 25, 26), the same organisms also represent an endogenous reservoir for potential recrudescence of symptomatic kala-azar. Such a reservoir places individuals previously infected with viscerotropic Leishmania, including patients properly treated, at some risk for future relapse. Clinically, this risk clearly increases if T cell (CD4 cell)-dependent mechanisms become impaired (2, 16, 22, 24).

Experimental studies in mouse models of visceral infection, including those using Leishmania donovani in initially susceptible, but self-curing wild-type (WT) BALB/c and C57BL/6 mice, have identified acquired host responses that 1) induce initial resistance (1, 2, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40), 2) maintain immunity and prevent spontaneous relapse (11, 12), and 3) impart solid resistance to rechallenge (10). These three basic responses are T cell-dependent; involve an array of cytokines including IL-12, IFN-{gamma}, and TNF; and are expressed in the tissues by granulomatous inflammation and macrophage activation (1, 2, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42). However, depending upon the acquired antileishmanial response tested and the model of visceral infection used, specific requirements for sensitized CD4 and/or CD8 cells and individual activating cytokines may vary (10, 11, 27, 39, 42, 43). Thus, it seemed reasonable to consider that prevention of relapse of chronic infection after antileishmanial chemotherapy might reflect distinct host defense mechanisms as well.

Prior experimental and clinical observations have made it clear that the protective posttreatment mechanism in visceral infection requires T cells (2, 5, 11, 16, 22, 44). To learn more about this response, which bears conversely on how relapse may occur in treated kala-azar, we tested outcome after chemotherapy in L. donovani-infected mice deficient in a spectrum of antileishmanial mechanisms. AmB was used in this study because, unlike the experimental effect of Sb, AmB’s leishmanicidal activity is direct and fully expressed initially in both T cell- and cytokine-deficient animals (1, 31, 34, 35, 36, 37, 40, 45, 46).


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 Disclosures
 References
 
Mice

Twenty to 30 gram female C57BL/6 and BALB/c mice purchased from The Jackson Laboratory were used as controls. Twenty to 30 gram female athymic (nude), CD4–/–, CD8–/–, and bg/bg–/– (beige) mice on a C57BL/6 background were also purchased from The Jackson Laboratory. Breeding pairs of gene-disrupted (knockout (KO)) mice on a C57BL/6 background were originally obtained from the following sources: CD40L–/–, ICAM-1-deficient, and IFN-{gamma}–/– (The Jackson Laboratory); respiratory burst (phagocyte NADPH oxidase (phox))-deficient gp91phox–/–, Dr. M. Dinauer (Indiana University Medical Center, Indianapolis, IN) (35); inducible NO synthase (iNOS)–/– and gp91phox –/–/iNOS–/– (double KO), Dr. C. Nathan (Weill Medical College, New York, NY) (35, 47); and IL-18–/–, Dr. C. Biron (Brown University School of Medicine, Providence, RI) (48). Breeding pairs of IFN-{gamma}–/–, IL-12p35–/–, and IL-12p40–/– mice on a BALB/c background were obtained from The Jackson Laboratory. Male and female KO mice were used in a random fashion, and bred mice were 6–13 wk old when challenged with L. donovani. These studies were reviewed and approved by the institutional animal care and use committee of Weill Medical College.

Visceral infection and tissue response

Groups of three to five mice were injected via the tail vein with 1.5 x 107 hamster spleen-derived L. donovani amastigotes (1 Sudan strain) (40). Visceral infection was followed microscopically using Giemsa-stained liver imprints in which liver parasite burdens were measured by blinded counting of the number of amastigotes per 500 cell nuclei x liver weight (milligrams; Leishman-Donovan units (LDU)) (40). The histologic response to infection was assessed microscopically in liver sections stained with H&E (42).

Response to AmB treatment

Starting 2 wk after infection, mice received three alternate-day i.p. injections of AmB (Gensia Laboratories), given at an optimal dose (5 mg/kg) on days 14, 16, and 18 (45). Liver parasite burdens were determined 14 and 21 days and 9 wk after treatment (12 wk after infection). Initial killing induced by AmB (percent reduction in parasite burden) was determined by comparing day 21 LDU to day 14 LDU (40). Differences between mean values were analyzed by two-tailed Student’s t test.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 Disclosures
 References
 
Posttreatment suppression of infection requires T cells

In initially susceptible WT C57BL/6 mice with established L. donovani infection, AmB injections on days 14, 16, and 18 reduced liver parasite burdens by 91% on day 21 (Fig. 1A). Nine weeks later, parasite burdens in treated animals remained low at levels similar to those in untreated C57BL/6 controls at wk 12 (53 ± 12 LDU; two experiments; n = 8 mice). (The latter, like WT BALB/c mice, acquire resistance by wk 4 and spontaneously show near-resolution of L. donovani hepatic infection by wk 8 (27, 40)). In wk 12 liver sections from treated C57BL/6 mice, intracellular amastigotes were scarce, and tissue inflammation, expressed earlier during wk 2–4 as epitheloid granulomas (not shown) (40), had largely involuted (Fig. 2A).



View larger version (19K):
[in this window]
[in a new window]
  		FIGURE 1. Outcome of L. donovani infection after AmB treatment in WT and T cell- and CD40L-deficient C57BL/6 mice. Two weeks after challenge, all mice received AmB on days 14, 16, and 18; liver parasite burdens were determined on day +14, day +21, and 9 wk after treatment (wk 12). A, WT ({circ}) vs nude mice (•). B, Nude (•) vs CD4 ({square}) and CD8 cell KO mice ({blacksquare}). C, WT ({circ}) vs CD40L KO mice (•). Results are from two (A and B) or three (C) experiments and indicate the mean ± SEM value per group per time point for eight to 11 mice. *, p < 0.05 vs wk 3 value.

 


View larger version (165K):
[in this window]
[in a new window]
  		FIGURE 2. Histologic reaction in livers of infected WT and T cell- and CD40L-deficient C57BL/6 mice 9 wk after AmB treatment (12 wk after L. donovani challenge). WT (A), nude (B), CD4 cell-deficient (C), CD8 cell-deficient (D), and CD40L-deficient (E) mice. Livers of treated nude (B) and CD40L KO (E) mice show large collections of replicating amastigotes (arrows), whereas few parasites are visible in sections from treated WT (A) or CD4-deficient (C) or CD8-deficient (D) mice. Original magnification, x200.

 
Athymic (nude) C57BL/6 mice, which did not control visceral infection (3988 ± 433 LDU at wk 12; two experiments; n = 9 mice), also showed an intact initial response to AmB, with 97% killing by day 21 (Fig. 1A). However, mirroring observations made in nude BALB/c mice (11), infection re-emerged in treated T cell-deficient animals at wk 12, yielding heavily parasitized liver foci with little inflammatory reaction (Figs. 1A and 2B).

Response to AmB in CD4 and CD8 cell-deficient mice

CD4 and CD8 KO mice were next tested in parallel with WT and nude animals to determine whether one T cell subset primarily acts to prevent relapse after chemotherapy. Consistent with findings in WT mice depleted of CD4 or CD8 cells by mAb injections (27), untreated CD4 and CD8 KOs failed to control L. donovani replication. At wk 12, liver burdens were high (3103 ± 291 and 3610 ± 315 LDU, respectively, vs 98 ± 16 LDU in WT mice; two experiments; n = 8–12 mice/group), and granuloma assembly was impaired (not shown). In response to AmB given during wk 3, parasite killing in CD4 and CD8 KO mice was comparable and similar to that in nude mice (88–93% liver parasite killing by day 21; Fig. 1B). Thereafter, however, posttreatment outcome in these three groups of mice clearly diverged, because infection did not recur in livers of CD4- or CD8-deficient mice. This result indicated that either CD4 or CD8 cells could provide the required T cell mechanism. The wk 12 liver histologic appearance in treated CD4 and CD8 KO mice was also similar (Fig. 2, C and D), showing evidence of residual inflammation and few visible amastigotes.

NK cell-deficient mice

Recurrent infection in treated nude mice indicated that NK cells retained in these animals were not sufficient to suppress parasite replication. However, NK cells may help to control L. donovani in T cell-intact mice, albeit in a limited fashion (10, 49). Therefore, euthymic beige mice, deficient in NK cell lytic activity (10), were also treated on days 14, 16, and 18 after infection. In these mice, AmB induced 94% killing by day 21 (two experiments; not shown), and liver parasite burdens in treated as well as untreated beige mice were low at wk 12 (88 ± 21 and 136 ± 14 LDU, respectively; n = 7–9 mice/group). Thus, NK cell lytic activity did not appear to contribute to posttreatment parasite suppression.

Response in CD40L-deficient mice

CD40:CD40L T cell costimulation, which can be expressed in CD4 and CD8 cells (50), regulates antileishmanial defense by optimizing IL-12 production, shaping the Th1 cell-type response, and inducing macrophage activation via T cell secretion of IFN-{gamma} (40, 51, 52). Not surprisingly, CD40L KO mice fail to control L. donovani replication at wk 8 (40), and in two new experiments extended in this study to wk 12, liver parasite burdens reached remarkably high levels (7636 ± 909 LDU; three experiments; n = 10 mice). Although these mice are AmB responsive (40) and showed 93% parasite killing on day 21 (Fig. 1C), relapse seemed assured in the absence of CD40L once the drug effect had waned. This prediction was borne out by the >20-fold increase in parasite burdens between wk 3 and 12 in treated CD40L KOs (Fig. 1C). Infection recurred despite granulomatous responses at the majority of parasitized liver foci (Fig. 2E), indicating, as in untreated CD40L KO mice (40), that CD40L is required for control of L. donovani, but not for late-stage granuloma assembly.

Posttreatment recurrence in cytokine-deficient mice

IFN-{gamma} and IL-12. Multiple cytokines participate in initial as well as memory responses in L. donovani infection (1, 10, 11, 28, 29, 30, 31, 32, 33, 34, 37, 39). Along with IL-12, for example, IFN-{gamma} and TNF interdigitate prominently in macrophage activation and acquired resistance; if one of the three is deficient, visceral infection does not come under control (1, 31, 32, 33, 34, 37, 53). Therefore, although AmB retains its initial leishmanicidal activity in the absence of IL-12, IFN-{gamma}, or TNF (31, 34, 37), outgrowth of surviving parasites would be anticipated in animals lacking these cytokines. This expectation was recently confirmed in TNF KO mice (37).

The experiments in Figs. 3 and 4 in BALB/c KO mice extend this posttreatment analysis to IFN-{gamma} and IL-12. In untreated IFN-{gamma} and IL-12p35 KO mice, liver parasite burdens at wk 12 were high (5843 ± 621 and 3825 ± 222 LDU, respectively; two or three experiments; n = 9–12 mice), far exceeding wk 12 values in untreated WT BALB/c controls (81 ± 22 LDU; two experiments; n = 9 mice). Although both groups of cytokine-deficient mice also showed similar initial responses to AmB (91–98% killing by day 21; Fig. 3A), parasite burdens and histologic findings were strikingly different at wk 12 (Fig. 3A and Fig. 4, A–D). IFN-{gamma} KO mice obviously relapsed after therapy, whereas IL-12p35 KOs did not, indicating posttreatment evolution to an IL-12-independent mechanism. The requirement for IFN-{gamma}, also demonstrated in IFN-{gamma}-deficient C57BL/6 mice (Fig. 3A), was underscored by reconstituting C57BL/6 nude mice with spleen cells from WT vs IFN-{gamma} KO animals (Fig. 5). In contrast to WT spleen cells, which enabled suppression of parasite replication after AmB, transfer of IFN-{gamma}-deficient cells provided little protective posttreatment effect.



View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 3. Outcome of infection in cytokine-deficient mice treated with AmB during wk 3 as described in Fig. 1. A, WT, IFN-{gamma}- and IL-12 (IL-12p35)-deficient mice BALB/c mice, and IFN-{gamma}-deficient C57BL/6 mice ({blacksquare}). B, WT and IL-12p35- and IL-12p40-deficient BALB/c mice. Results in A and B are from two or three experiments and indicate the mean ± SEM values for seven to 13 mice per group per time point. *, p < 0.05 vs wk 3 value.

 


View larger version (200K):
[in this window]
[in a new window]
  		FIGURE 4. Liver histologic appearance in cytokine-deficient mice 12 wk after infection. A, C, and E, Untreated mice; B, D, and F, mice given AmB 9 wk previously. A and B, IFN-{gamma}-deficient BALB/c mice; C and D, IL-12p35–deficient BALB/c mice; E and F, IL-12p40-deficient BALB/c mice. All untreated mice (A, C, and E) show remarkably heavy infection (arrows) and little inflammatory response. Posttreatment, recrudescence developed only in IFN-{gamma} KO mice (B), whereas IL-12p35 (D) and IL-12p40 (F) KO mice show few visible amastigotes (arrow in D) and little residual inflammatory response. Original magnification, x200.

 


View larger version (21K):
[in this window]
[in a new window]
  		FIGURE 5. Response of reconstituted nude C57BL/6 mice to AmB given during wk 3. Conditions were as described in Fig. 1, except that 1 day before L. donovani challenge, nude mice received no cells or i.v. transfer of 5 x 106 unfractionated spleen cells (27 ) from WT or IFN-{gamma}-deficient C57BL/6 mice. Results are from two experiments and indicate the mean ± SEM values for six or seven mice per group per time point. *, p < 0.05 vs wk 3 value.

 
IL-18 and IL-23. IL-12 is the primary IFN-{gamma}-inducing cytokine in this L. donovani model (31, 32, 33). However, the preceding wk 12 observations pointed to an effect of other IFN-{gamma}-inducing cytokines and prompted testing roles for IL-18 and IL-23 (48, 54, 55). At both wk 2 and 4, liver parasite burdens were significantly higher in untreated C57BL/6 IL-18 KO mice vs WT animals; however, KO mice spontaneously controlled infection by wk 8 (two experiments; data not shown). At wk 12, liver burdens remained low in untreated IL-18 KO mice (164 ± 32 LDU) and were still lower in IL-18 KOs given AmB during wk 3 (24 ± 7 LDU; n = 8 mice/group).

To gauge the contribution of IL-23, BALB/c IL-12p40 KO mice (deficient in both IL-12 and IL-23) (38, 54, 55, 56) were tested in parallel with IL-12p35 KO mice (deficient in IL-12 alone) (31). Untreated IL-12p40–/– mice did not control L. donovani replication at wk 12 (6012 ± 649 LDU; two experiments; n = 9 mice). However, these KO animals responded to AmB (89% killing on day 21) and, like p35-deficient mice, did not show recurrent visceral infection at wk 12 (Fig. 3B and Fig. 4, E and F). Thus, by itself and akin to IL-18, IL-23 was not apparently required to prevent relapse after therapy, leaving open the question of what late-acting compensatory mechanism induces IL-12-independent IFN-{gamma} in the posttreatment state.

Response to AmB in mice deficient in monocyte influx and macrophage leishmanicidal mechanisms. Blood monocytes, required effector cells in this model (57), initially use the endothelial cell adhesion molecule, ICAM-1, to enter infected liver foci and populate developing L. donovani-induced granulomas (36). Along with resident macrophages, influxing monocytes respond to IFN-{gamma} and TNF activation with intracellular killing (57). The latter effect (and thus overall control of tissue infection) is achieved primarily via iNOS-derived reactive nitrogen intermediates; respiratory burst (phox)-derived reactive oxygen intermediates play an early, but transient, role (35). Therefore, to complete this analysis, we focused on mononuclear phagocyte mechanisms and tested the outcome of AmB treatment in mice deficient in ICAM-1 and in iNOS and/or phox.

ICAM-1-deficient mice. In ICAM-1 KO mice, initially unrestrained L. donovani replication is controlled after wk 4, but visceral infection does not resolve properly; wk 12 liver burdens are ~10-fold higher than in WT C57BL/6 mice (36). As reported previously (36) and observed in two new experiments, ICAM-1 KO mice treated during wk 3 responded to AmB (87% parasite killing; data not shown). At wk 12, liver burdens remained substantially elevated in untreated KO mice (969 ± 99 LDU; n = 9 mice); however, there was no recurrence of infection in AmB-treated animals (92 ± 38 LDU; n = 10 mice). The results from these two experiments suggested that the ICAM-1 mechanism had also become dispensable posttreatment.

Phox-, iNOS-, and doubly-deficient mice. In a prior study, L. donovani-infected phox KO and iNOS KO mice, treated with AmB during wk 3, showed near-identical initial (> 90% parasite killing) as well as long-term responses (little or no increase in liver burdens at wk 12) (34). For phox-deficient mice, such a posttreatment outcome was not surprising, because these animals express iNOS activity (35, 58) and, after a transient increase in susceptibility, spontaneously resolve liver infection to low levels without treatment (35). In AmB-treated iNOS KO mice, however, the absence of relapse was entirely unexpected, because despite a retained phox mechanism and vigorous granuloma assembly (34, 35), untreated iNOS-deficient mice permit progressive parasite replication throughout 12 wk of infection (35).

Therefore, mice doubly-deficient in phox and iNOS (47) were examined to test the hypothesis that an entirely unrelated macrophage mechanism was active in preventing recurrent infection after treatment. As expected, liver parasite burdens in untreated animals at wk 12 were low in phox-deficient (77 ± 39) and high in both iNOS-deficient (3140 ± 291) and double-KO mice (4178 ± 486; two or three experiments; n = 7–17 mice/group; Fig. 6). In response to AmB treatment, initial leishmanicidal activity was similar in the three groups of deficient animals (97–98% killing; Fig. 7). At wk 12, infection did not recur in the absence of either phox or iNOS alone, as anticipated (34), but remarkably, also did not recur in mice lacking both pathways (Figs. 6D and 7). Thus, at the level of the parasitized macrophage, neither of this effector cell’s primary antileishmanial mechanisms was required to prevent relapse of chronic infection in the liver after chemotherapy.



View larger version (165K):
[in this window]
[in a new window]
  		FIGURE 6. Photomicrographs of liver sections from mice deficient in macrophage leishmanicidal mechanisms 12 wk after infection. A, Untreated phox KO mice have largely cleared infection, whereas untreated iNOS KO (B) and iNOS/phox double-KO mice (C) show heavily parasitized Kupffer cells (arrows) surrounded by intense, but ineffective, granulomatous inflammation. D, Double-KO mice treated 9 wk previously with AmB show only scattered residual granulomas and no recurrent infection. Original magnification, x200.

 


View larger version (23K):
[in this window]
[in a new window]
  		FIGURE 7. Outcome of liver infection in mice deficient in macrophage leishmanicidal mechanisms after AmB treatment during wk 3 as described in Fig. 1 in iNOS KO, phox KO, and iNOS/phox double-KO (DKO) mice. Results are from two or three experiments and indicate the mean ± SEM values for six to 13 mice per group per time point. LDU values for phox, iNOS, and double KO mice were 41 ± 8, 49 ± 11, and 35 ± 11 at wk 3 and 6 ± 3, 9 ± 3, and 37 ± 14 at wk 12, respectively.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
Disclosures
 References
 
In the basic expressions of acquired resistance in this model of experimental visceral leishmaniasis, acquisition of initial resistance, resistance to reinfection, and maintenance of immunity after spontaneous self-cure (1, 10, 11, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 57), T cells, cytokines, and activated macrophages interdigitate as recognized cornerstones of host defense. However, in this spectrum of acquired responses, distinguishing features can be identified, including differing requirements for participation of particular T cells (e.g., CD4, CD8, or both subsets) (10, 11, 27) and/or cytokines (e.g., IFN-{gamma} is not required in resistance to rechallenge) (10). Similarly, regulation of the posttreatment response tested in this study also showed separate T cell and cytokine requirements compared with those, for example, of acquired resistance (Table I). Together, these observations underscore 1) the general flexibility of host antileishmanial programs, including the likely presence of multiple compensatory pathways, and 2) specific modification (evolution) of mechanisms in response to varying experimental conditions. Examples of the latter include the stage of visceral infection examined (acute vs chronic), the use of intentional rechallenge, and whether conversion to the chronic state develops spontaneously or is induced by chemotherapy as in the present study (10, 11, 27, 42).


View this table:
[in this window]
[in a new window]
  		Table I. Initial vs posttreatment acquired immune responses in L. donovani infection in the liver

 
Table I, which summarizes mechanisms in this model of initial acquired resistance vs prevention of recurrence after chemotherapy, should be viewed with some caution, however. First, different stages of infection were analyzed, and different experimental hosts were used (e.g., C57BL/6 and BALB/c mice and mAb-treated WT and KO mice). Second, different results might have been generated if chronically infected WT mice had been injected after treatment with cell-depleting or cytokine-neutralizing mAb or treated with an iNOS inhibitor (13), rather than studying genetically deficient KO mice. Third, the latter may express responses or mechanisms not ordinarily observed in or used in the same fashion by normal animals (37). Nevertheless, testing in cell-, cytokine-, or enzyme-deficient KO animals can readily demonstrate the presence of such compensatory-type mechanisms as well as identify dispensable factors. Fourth, the initial parasite-lowering effect of treatment should not be discounted because it may have provided the opportunity for alternative host immune responses to develop and be expressed during the posttreatment period. In addition, because responses to L. donovani can be organ specific (32), results for infection in the spleen or bone marrow in KO mice might also differ from those observed in this study.

To maintain the intracellular L. donovani amastigotes that escape chemotherapy in a long-term quiescent state, the chronically infected host may also have more than one basic mechanism upon which to draw. For example, humoral factors might play some protective role, although relapse in human infection occurs despite the presence of specific Ab (2). Much more likely, then, is an intracellular response, such as characterized in this report, which proved to be T cell-dependent and cytokine regulated, although independent of the activated macrophage’s primary leishmanicidal mechanisms.

In these experiments, prevention of posttreatment recurrence 1) was directed equally well by CD4 or CD8 T cells, 2) involved CD40L signaling, and 3) required IFN-{gamma} (and TNF (37)), presumably to maintain a certain level of macrophage activation. Although CD4 cells probably exert multiple effects (27, 59), the role of CD8 cells in macrophage activation in this L. donovani model has been less well appreciated, albeit previously noted (27, 60). Nevertheless, like CD4 cells, CD8 cells express CD40L and secrete IFN-{gamma}, TNF, and a variety of chemokines (27, 50, 60, 61). Thus, the effects of both cytokines, possibly mediated by CD40L:CD40 signaling (62), may underlie the capacity of either T cell subset to successfully orchestrate protective posttreatment responses. Antileishmanial effects of CD8 cells might also relate to separate pathways, including, perhaps, the granzyme-perforin mechanism (60, 61, 63).

Our results in cytokine-deficient mice suggest that although IFN-{gamma} (present report) and TNF (37) probably act in concert after treatment to suppress the replication of residual intracellular liver parasites, this effect does not require IL-12, the primary IFN-{gamma}-inducing cytokine in this model (31). IL-23 and IL-18 also induce or enhance IFN-{gamma} secretion (48, 54, 55); however, neither cytokine was by itself required to prevent posttreatment relapse. These observations may well reflect an alternative IFN-{gamma}-producing pathway, apparently dependent on TNF, but independent of IL-12, IL-23, and IL-18, recently described in IL-12p40–/–/IL-18–/– double-KO mice infected with Mycobacterium tuberculosis (55). Other IFN-{gamma}-inducing stimuli, IL-2 (28), IL-15 (64), IL-27 (65), or possibly IL-21 (66), may also be worth investigating in the chronically infected host in this posttreatment model.

Because L. donovani resides within tissue macrophages in all stages of visceral infection, the logical target and role for IFN-{gamma} and TNF in maintaining a quiescent posttreatment state is the parasitized macrophage and its activation. Our results in livers of mice doubly-deficient in phox and iNOS demonstrate, however, that neither of these leishmanicidal pathways is required to prevent posttreatment recurrence. Because prevention of relapse requires inhibition of replication, but not necessarily intracellular parasite killing, it is possible that in this particular setting, IFN-{gamma} and TNF evolve to regulate a leishmanistatic, rather than a leishmanicidal, mechanism. Either way, the results in double-knockout mice clearly uncover the presence and activity of a novel, compensatory antileishmanial mechanism not induced by L. donovani alone, but in this case triggered by AmB. Whether any form of effective antileishmanial chemotherapy can induce this macrophage mechanism (see below) will be clarified by testing Sb and/or miltefosine in iNOS/phox double-knockout mice. These same animals also show spontaneous macrophage antibacterial activity (47). Although the basis of this latter effect in doubly-deficient mice has not yet been identified, p47 GTPases have recently been implicated in a separate IFN-{gamma}-inducible, iNOS- and phox-independent, macrophage antimicrobial mechanism (67, 68). This mechanism, which is active against intracellular pathogens (68), might also operate in L. donovani infection.

Although not investigated in this study, default to a suppressive-type cytokine response, mediated by IL-10 (41, 69) or, perhaps, IL-4, IL-13, or TGF-{beta} (1, 2, 38, 70, 71), might possibly have fostered posttreatment relapse in IFN-{gamma}- or CD40L-deficient animals (51, 52, 72). However, outcomes in AmB-treated TNF and IL-12 KO mice are at odds with this consideration, because TNF KO mice are not known to default to a Th2 cell-type response, but relapse after AmB (37), and IL-12p35 KO mice show evidence of default (31), but do not relapse after treatment (Fig. 3). In addition, WT BALB/c mice, induced by immunization to respond to L. donovani with an IL-4/IL-10-mediated noncure phenotype (70), also show no late relapse of liver infection after initial AmB treatment (our unpublished observations).

Finally and as suggested above, it is also fair to consider whether the results of this study are drug specific and related only to effects induced by AmB, an agent with recognized immunomodulatory activity (73, 74, 75, 76). Sb, unlike AmB, requires T cells, CD40L, IFN-{gamma}, IL-12, and TNF for expression of its in vivo leishmanicidal effect (31, 34, 37, 40, 45, 46); thus, Sb could not be used to induce near-cure in mice deficient in these factors to set the stage for testing for posttreatment relapse. However, similar to the effects of AmB, there is no late recurrence of L. donovani liver infection in Sb-treated ICAM-1 or iNOS KO mice (34, 36). Miltefosine, like AmB, is active initially in T cell- and cytokine-deficient mice infected with L. donovani (44); prevention of relapse after miltefosine therapy also requires T cells (77). In preliminary experiments in which IFN-{gamma} and IL-12p35 KO mice were treated during wk 3 with miltefosine (44), liver infection recurred at wk 12 in IFN-{gamma}-deficient, but not IL-12-deficient, mice (not shown), similar to the findings in AmB-treated animals. These results with other forms of antileishmanial chemotherapy suggest that the mechanisms described in this report may be generally applicable to prevention of posttreatment relapse in experimental visceral infection.


   Disclosures
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
References
 
The authors have no financial conflict of interest.


   Acknowledgments
 
Drs. Shizu Akira and Kiyoshi Takeda (48 ) originally developed the IL-18–/– mice used in this study.


   Footnotes
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by National Institutes of Health Research Grant AI16963. Back

2 Address correspondence and reprint requests to Dr. Henry W. Murray, Box 136, 1300 York Avenue, New York, NY 10021. E-mail address: hwmurray{at}med.cornell.edu Back

3 Abbreviations used in this paper: Sb, pentavalent antimony; AmB, amphotericin B; iNOS, inducible NO synthase; KO, knockout; LDU, Leishman-Donovan unit; phox, phagocyte NADPH oxidase; WT, wild type. Back

4 Sb remains conventional treatment for visceral leishmaniasis except in Bihar State, India (~45% of the world’s cases), where Sb resistance has made AmB the first-line parenteral therapy. Oral miltefosine was approved for use in India in 2002 (1 2 ). Back

Received for publication November 17, 2004. Accepted for publication January 13, 2005.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 Disclosures
 References
 

  1. Murray, H. W.. 2001. Clinical and experimental advances in treatment in visceral leishmaniasis. Antimicrob. Agents Chemother. 45:2185.[Free Full Text]
  2. Murray, H. W.. 2004. Progress in treatment of a neglected disease: visceral leishmaniasis. Expert Rev. Anti-Infect. Ther. 2:279.
  3. Wijers, D. J. B.. 1971. A ten years’ study of kala-azar in Tharaka (Meru District, Kenya). II. Relapses. E. Afr. Med. J. 48:551.[Medline]
  4. Nyakundi, P. M., K. M. A. Wasunna, J. R. Rashid, G. S. Gachichi, J. Mbugua, G. Kirigi, J. Muttunga. 1994. Is one year follow-up justified in kala-azar post-treatment?. E. Afr. Med. J. 71:453.[Medline]
  5. Ritmeijer, K., K. Veeken, Y. Melaku, G. Leal, R. Amsalu, J. Seaman, R. N. Davidson. 2001. Ethiopian visceral leishmaniasis: generic and proprietary sodium stibogluconate are equivalent; HIV co-infected patients have a poor outcome. Trans. R. Soc. Trop. Med. Hyg. 95:668.[Medline]
  6. Sundar, S., T. K. Jha, C. P. Thakur, J. Engel, J. Sindermann, C. Fischer, K. Junge, A. Bryceson, J. Berman. 2002. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 347:1739.[Abstract/Free Full Text]
  7. Saravia, N. G., K. Weigle, I. Segura, S. H. Giannini, R. Pacheco, L. A. Labrada, A. Goncalves. 1990. Recurrent lesion in human Leishmania braziliensis infection: reactivation or reinfection?. Lancet 336:398.[Medline]
  8. Rossel, R. A., R. J. Duran, O. Rossel, A. M. Rodriguez. 1992. Is leishmaniasis ever cured?. Trans. R. Soc. Trop. Med. Hyg. 86:251.[Medline]
  9. Aebischer, T. S., F. Moody, E. Handman. 1993. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host. Infect. Immun. 61:220.[Abstract/Free Full Text]
  10. Murray, H. W., K. E. Squires, G. D. Miralles, M. Y. Stoeckle, A. Granger, A. Piperno, C. Bogdan. 1992. Acquired resistance and granuloma formation in experimental visceral leishmaniasis: differential T cell and lymphokine roles in initial vs. established immunity. J. Immunol. 148:1858.[Abstract]
  11. Murray, H. W., J. Hariprashad, R. Fichtl. 1996. Models of relapse of experimental visceral leishmaniasis. J. Infect. Dis. 173:1041.[Medline]
  12. Rousseau, D., I. Suffia, B. Ferrua, P. Philip, Y. Le Fichoux, J. Kubar. 1998. Prolonged administration of dexamethasone induces limited reactivation of visceral leishmaniosis in chronically infected BALB/c mice. Eur. Cytokine Network 9:655.[Medline]
  13. Stenger, S., N. Dornhauser, H. Thuring, M. Rollinghoff, C. Bogdan. 1996. Reactivation of latent leishmaniasis by inhibition of inducible nitric oxide synthase. J. Exp. Med. 183:1501.[Abstract/Free Full Text]
  14. Belkaid, Y., K. F. Hoffman, S. Mendez, K. Kamhawi, M. C. Udey, T. A. Wynn, D. L. Sacks. 2001. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapuetic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194:1497.[Abstract/Free Full Text]
  15. Cortadellas, O.. 2003. Initial and long-term efficacy of a lipid emulsion of amphotericin B desoxycholate in the management of canine leishmanisis. J. Vet. Intern. Med. 17:808.[Medline]
  16. Morales, M. A., I. Cruz, J. M. Rubio, C. Chicharro, C. Canavanta, F. Laguna, J. Alvar. 2002. Relapses versus reinfections in patients coinfected with Leishmania infantum and human immunodeficiency virus type 1. J. Infect. Dis. 185:1533.[Medline]
  17. Dereure, J., T. H. Duong, T. Lavabre-Bertrand, G. Cartron, F. Bastides, D. Richard-Lenoble, J. P. Dedet. 2003. Visceral leishmanisis: persistence of parasites in lymph nodes after clinical cure. J. Infect. 47:77.[Medline]
  18. Mendonca, M. G., M. E. F. de Brito, E. H. G. Rodriquez, V. Bandeira, M. L. Jardim, F. G. C. Abath. 2004. Persistence of Leishmania parasites in scars after clinical cure of American cutaneous leishmaniasis: is there a sterile cure?. J. Infect. Dis. 189:1018.[Medline]
  19. Le Fichoux, Y., J. F. Quaranta, J. P. Aufeuvre, A. Lelievre, P. Marty, I. Suffia, D. Rousseau, J. Kubar. 1999. Occurrence of Leishmania infantum parasitemia in asymptomatic blood donors living in an area of endemicity in southern France. J. Clin. Microbiol. 37:1953.[Abstract/Free Full Text]
  20. Gama, M. E. A., J. M. L. Costa, J. C. R. Pereira, C. C. C. Gomes, C. E. P. Corbett. 2004. Serum cytokine profile in the subclinical form of visceral leishmaniasis. Braz. J. Med. Biol. Res. 37:129.[Medline]
  21. Meller-Melloul, C., C. Farnarier, S. Dunan, B. Faugere, J. Franck, C. Mary, P. Bongrand, M. Quilici, S. Kaplanski. 1991. Evidence of subjects sensitized to Leishmania infantum on the French Mediterranean coast: differences in {gamma} interferon production between this population and visceral leishmaniasis patients. Parasite Immunol. 13:531.[Medline]
  22. Alvar, J., C. Canavate, B. Gutierrez-Solar, M. Jimenez, F. Laguna, R. Lopez-Velez, R. Molina, J. Moreno. 1997. Leishmania and human immunodeficiency virus coinfection: the first 10 years. Clin. Microbiol. Rev. 10:298.[Abstract]
  23. Sundar, S., S. G. Reed, S. Sharma, A. Mehrota, H. W. Murray. 1997. Circulating Th1 cell- and Th2 cell-associated cytokines in Indian patients with visceral leishmaniasis. Am. J. Trop. Med. Hyg. 56:522.
  24. Hernandez-Perez, J., M. Yebra-Bango, E. Jimenez-Martinez, C. Sanz-Moreno, V. Cuervas-Mons, L.A. Pulpon, A. Ramos-Martinez, J. Fernandez-Fernandez. 1999. Visceral leishmaniasis (kala-azar) in solid organ transplantation: report of five cases and review. Clin. Infect. Dis. 29:918.[Medline]
  25. Belkaid, Y., A. C. Piccirillo, S. Mendez, E. M. Shevach, D. L. Sacks. 2002. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 420:502.[Medline]
  26. Uzonna, J. E., G. Wei, D. Yurkowski, P. Bretscher. 2001. Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease. J. Immunol. 167:6967.[Abstract/Free Full Text]
  27. Stern, J. J., M. J. Oca, B. Y. Rubin, S. Anderson, H. W. Murray. 1988. Role of L3T4+ and Lyt-2+ cells in experimental visceral leishmaniasis. J. Immunol. 140:3971.[Abstract]
  28. Murray, H. W., G. D. Miralles, M. Y. Stoeckle, D. F. McDermott. 1993. Role and effect of interleukin-2 in experimental visceral leishmaniasis. J. Immunol. 151:929.[Abstract]
  29. Melby, P. C., Y.-Z. Yang, J. Cheng, W. Zhao. 1998. Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani. Infect. Immun. 66:18.[Abstract/Free Full Text]
  30. Murphy, M. L., S. Cotterell, M. Gorak, C. R. Engwerda, P. M. Kaye. 1998. Blockade of CTLA-4 enhances host resistance to the intracellular pathogen, Leishmania donovani. J. Immunol. 161:4153.[Abstract/Free Full Text]
  31. Murray, H. W., C. Montelibano, R. Peterson, J. P. Sypek. 2000. Interleukin 12 regulates the response to chemotherapy in experimental visceral leishmaniasis. J. Infect. Dis. 182:1497.[Medline]
  32. Engwerda, C. R., M. L. Murphy, S. E. Cotterell, S. C. Smelt, P. M. Kaye. 1998. Neutralization of IL-12 demonstrates the existence of discrete organ-specific phases in the control of Leishmania donovani. Eur. J. Immunol. 28:669.[Medline]
  33. Satoskar, A. R., S. Rodig, S. R. Telford, A. A. Satoskar, S. K. Ghosh, F. von Lichtenberg, J. R. David. 2000. IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic pathology. Eur. J. Immunol. 30:834.[Medline]
  34. Murray, H. W., S. Delph-Etienne. 2000. Role of endogenous {gamma} interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 68:288.[Abstract/Free Full Text]
  35. Murray, H. W., C. F. Nathan. 1999. Macrophage microbicidal mechanisms in vivo: reactive nitrogen vs. oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 189:741.[Abstract/Free Full Text]
  36. Murray, H. W.. 2000. Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation. Infect. Immun. 68:6294.[Abstract/Free Full Text]
  37. Murray, H. W., A. Jungbluth, E. Ritter, C. Montelibano, M. W. Marino. 2000. Visceral leishmaniasis in mice devoid of tumor necrosis factor and response to treatment. Infect. Immun. 68:6289.[Abstract/Free Full Text]
  38. Wilson, M. E., T. J. Recker, N. E. Rodriguez, B. M. Young, K. K. Burnell, J. A. Streit, J. N. Kline. 2002. The TGF-{beta} response to Leishmania chagasi in the absence of IL-12. Eur. J. Immunol. 32:3556.[Medline]
  39. Stager, S., J. Alexander, K. C. Carter, F. Brombacher, P. M. Kaye. 2003. Both interleukin-4 (IL-4) and IL-4 receptor {alpha} signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infect. Immun. 71:4804.[Abstract/Free Full Text]
  40. Murray, H. W., C. M. Lu, E. B. Brooks, R. E. Fichtl, J. L. DeVecchio, F. P. Heinzel. 2003. Modulation of T cell costimulation as immuno- or immunochemotherapy in experimental visceral leishmaniasis. Infect. Immun. 71:6453.[Abstract/Free Full Text]
  41. Murphy, M. L., U. Wille, E. N. Villegas, C. A. Hunter, J. P. Farrell. 2001. IL-10 mediates susceptibility to Leishmania donovani infection. Eur. J. Immunol. 31:2848.[Medline]
  42. Murray, H. W.. 2001. Tissue granuloma structure-function in experimental visceral leishmaniasis. Int. J. Exp. Pathol. 82:249.[Medline]
  43. Miralles, G. D., M. Y. Stoeckle, D. F. McDermott, F. D. Finkelman, H. W. Murray. 1994. Induction of Th1 and Th2 cell-associated cytokines in experimental visceral leishmaniasis. Infect. Immun. 62:1058.[Abstract/Free Full Text]
  44. Murray, H. W., S. Delph-Etienne. 2000. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanisms. J. Infect. Dis. 181:795.[Medline]
  45. Murray, H. W., J. Hariprashad, R. Fichtl. 1993. Treatment of experimental visceral leishmaniasis in a T cell-deficient host: response to amphotericin B and pentamidine. Antimicrob. Agents Chemother. 7:1504.
  46. Escobar, P., V. Yardley, S. L. Croft. 2001. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob. Agents Chemother. 45:1872.[Abstract/Free Full Text]
  47. Shiloh, M. U., J. D. MacMicking, S. Nicholson, J. E. Brause, S. Potter, M. Marino, F. Fang, M. Dinauer, C. Nathan. 1999. Phenotype of mice and macrophages deficient in both phagocyte oxidase and inducible nitric oxide synthase. Immunity 10:29.[Medline]
  48. Takeda, K., H. Tsutsui, H. T. Yoshimoto, O. Adachi, N. Yoshida, T. Kishimoto, H. Okamura, K. Nakanishi, S. Akira. 1998. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity 8:383.[Medline]
  49. Kirkpatrick, C. E., J. P. Farrell. 1982. Leishmaniasis in beige mice. Infect. Immun. 38:1208.[Abstract/Free Full Text]
  50. Kweon, M.-N., H. Kiyono. 2002. CD40L in autoimmunity and mucosally induced tolerance. J. Clin. Invest. 109:171.[Medline]
  51. Campbell, K. A., P. J. Ovendale, M. K. Kennedy, W. C. Fanslow, S. G. Reed, C. R. Maliszewski. 1996. CD40 ligand is required for protective cell-mediated immunity to Leishmania major. Immunity 4:283.[Medline]
  52. Soong, L., J.-C. Xu, I. S. Grewal, P. Kima, J. Sun, B. J. Longley, N. H. Ruddle, D. McMahon-Pratt, R. A. Flavell. 1996. Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. Immunity 4:263.[Medline]
  53. Tumang, M. C. T., C. Keogh, L. L. Moldawer, D. C. Helfgott, R. Teitelbaum, J. Hariprashad, H. W. Murray. 1994. Role and effect of TNF-{alpha} in experimental visceral leishmaniasis. J. Immunol. 153:768.[Abstract]
  54. Oppmann, B., R. Lesley, B. Blom, J. C. Timants, Y. Xu, B. Hunte, F. Vega, N. Yu, J. Wang, K. Singh, et al 2000. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biologic activities similar as well as from IL-12. Immunity 12:715.
  55. Kawakami, K., Y. Kinjo, K. Uezu, K. Miyagi, T. Kinjo, S. Yara, Y. Koguchi, A. Miyazato, K. Shibuya, Y. Iwakura, et al 2004. Interferon-{gamma} production and host protective response against Mycobacterium tuberculosis in mice lacking IL-12p40 and IL-18. Microbes Infect. 6:339.[Medline]
  56. Zubairi, S., S. L. Sanos, S. Hill, P. M. Kaye. 2004. Immunotherapy with OX40L-Fc or anti-CTLA-4 enhances local tissue responses and killing of Leishmania donovani. Eur. J. Immunol. 34:1.
  57. Cervia, J., H. Rosen, H. W. Murray. 1993. Effector role of blood monocytes in experimental visceral leishmaniasis. Infect. Immun. 61:1330.[Abstract/Free Full Text]
  58. Blos, M., U. Schleicher, F. J. S. Rochs, U. Meibner, M. Rollinghoff, C. Bogdan. 2003. Organ-specific and stage-dependent control of Leishmania major infection by inducible nitric oxide synthase and phagocyte NADPH oxidase. Eur. J. Immunol. 33:1224.[Medline]
  59. Reiner, S. L., R. M. Locksley. 1995. The regulation of immunity to Leishmania major. Annu. Rev. Immunol. 13:151.[Medline]
  60. Tsagozis, P., E. Karagouni, E. Dotsika. 2003. CD8+ T cells with parasite-specific cytotoxicity and a Tc1 profile of cytokine and chemokine secretion develop in experimental visceral leishmaniasis. Parasite Immunol. 25:569.[Medline]
  61. Harty, J. T., A. R. Tvinnereim, D. W. White. 2000. CD8+ T cell effector mechanisms in resistance to infection. Annu. Rev. Immunol. 18:275.[Medline]
  62. Grewal, I. S., R. A. Flavell. 1998. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16:111.[Medline]
  63. Bergmann, C. G., B. Parra, D. R. Hinton, C. Ramakrishna, K. C. Dowdell, S. A. Stohlman. 2004. Perforin and {gamma} interferon-mediated control of coronavirus central nervous system infection by CD8 T cells in the absence of CD4 T cells. Infect. Immun. 78:1739.
  64. Strengell, M., S. Matikainen, J. Siren, A. Lehtonen, D. Foster, I. Julkunen, T. Sareneva. 2003. IL-21 in syngery with IL-15 or IL-18 enhances IFN-{gamma} production in human NK and T cells. J. Immunol. 170:5465.
  65. Yoshida, H., S. Hamano, G. Senaldi, T. Covey, R. Faggioni, S. Mu, M. Xia, A. C. Wakeham, H. Nishina, J. Potter, et al 2001. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15:569.[Medline]
  66. Ma, H-L., M. J. Whitters, R. F. Konz, M. Senices, D. A. Young, M. J. Grusby, M. Collins, K. Dunussi-Joannopoulos. 2003. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-{gamma}. J. Immunol. 171:608.[Abstract/Free Full Text]
  67. MacMicking, J., G. A. Taylor, J. McKinney. 2003. Immune control of tuberculosis by IFN-{gamma}-inducible LRG-27. Science 302:654.[Abstract/Free Full Text]
  68. Taylor, G. A., C. G. Feng, A. Sher. 2004. P47 GTPases: regulators of immunity to intracellular pathogens. Nat. Rev. Immunol. 4:100.[Medline]
  69. Murray, H. W., C. M. Lu, S. Mauze, S. Freeman, A. L. Moreira, G. Kaplan, R. L. Coffman. 2002. Interleukin-10 (IL-10) in experimental visceral leishmaniasis and IL-10 receptor blockade as immunotherapy. Infect. Immun. 70:6284.[Abstract/Free Full Text]
  70. Murray, H. W., J. Hariprashad, R. L. Coffman. 1997. Behavior of visceral Leishmania donovani in an experimentally-induced Th2 cell-associated response model. J. Exp. Med. 185:867.[Abstract/Free Full Text]
  71. Babaloo, Z., P. M. Kaye, M. B. Eslami. 2001. IL-13 in Iranian patients with visceral leishmaniaisis: relationship to other Th2 and Th1 cytokines. Trans. R. Soc. Trop. Med. Hyg. 95:1.[Medline]
  72. Wang, Z. E., S. L. Reiner, S. Zheng, D. K. Dalton, R. M. Locksley. 1994. CD4+ effector cells default to the Th2 pathway in interferon {gamma}-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367.[Abstract/Free Full Text]
  73. Tokuda, Y., M. Tsuji, M. Yamazaki, S. Kimura, S. Abe, H. Yamaguchi. 1993. Augmentation of murine tumor necrosis factor productrion by amphotericin B in vitro and in vivo. Antimicrob. Agents Chemother. 37:2228.[Abstract/Free Full Text]
  74. Mozaffarian, N., J. W. Berman, A. Casadevall. 1997. Enhancement of nitric oxide synthesis by macrophages represents an additional mechanism of action for amphotericin B. Antimicrob. Agents Chemother. 41:1825.[Abstract]
  75. Vonk, A. G., M. G. Netea, N. E. Denecker, I. C. Verschueren, J. W. van der Meer, B. J. Kullberg. 1998. Modulation of the pro- and anti-inflammatory cytokine balance by amphotericin B. J. Antimicrob. Chemother. 42:469.[Abstract/Free Full Text]
  76. Rogers, P. D., J. K. Jenkins, S. W. Chapman, K. Ndebele, B. A. Chapman, J. D. Cleary. 1998. Amphotericin B activation for human genes encoding for cytokines. J. Infect. Dis. 178:1726.[Medline]
  77. Murray, H. W.. 2000. Suppression of posttreatment recurrence of experimental visceral leishmaniasis in T cell-deficient mice by oral miltefosine. Antimicrob. Agents Chemother. 44:3235.[Abstract/Free Full Text]
  78. Squires, K. E., R. D. Schreiber, M. J. McElrath, B. Y. Rubin, S. L. Anderson, H. W. Murray. 1989. Experimental visceral leishmaniasis: role of endogenous interferon-{gamma} in host defense and tissue granulomatous response. J. Immunol. 143:4244.[Abstract]
  79. Murray, H. W., J. Cervia, J. Hariprashad, A. P. Taylor, M. Y. Stoeckle, H. Hockman. 1995. Effect of granulocyte-macrophage colony-stimulating factor in experimental visceral leishmaniasis. J. Clin. Invest. 95:1183.
  80. Taylor, A., H. W. Murray. 1997. Intracellular antimicrobial activity in the absence of interferon-{gamma}: effect of interleukin 12 in experimental visceral leishmaniasis in interferon-{gamma} gene-disrupted mice. J. Exp. Med. 185:1231.[Abstract/Free Full Text]
  81. Villegas, E. N., L. A. Lieberman, S. R. Carding, C. A. Hunter. 2002. Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of {gamma} interferon. Infect. Immun. 70:4757.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
A. Banerjee, M. De, and N. Ali
Complete Cure of Experimental Visceral Leishmaniasis with Amphotericin B in Stearylamine-Bearing Cationic Liposomes Involves Down-Regulation of IL-10 and Favorable T Cell Responses
J. Immunol., July 15, 2008; 181(2): 1386 - 1398.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
S. Bhowmick, R. Ravindran, and N. Ali
gp63 in Stable Cationic Liposomes Confers Sustained Vaccine Immunity to Susceptible BALB/c Mice Infected with Leishmania donovani
Infect. Immun., March 1, 2008; 76(3): 1003 - 1015.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. Saha, S. Mondal, R. Ravindran, S. Bhowmick, D. Modak, S. Mallick, M. Rahman, S. Kar, R. Goswami, S. K. Guha, et al.
IL-10- and TGF-beta-Mediated Susceptibility in Kala-azar and Post-kala-azar Dermal Leishmaniasis: The Significance of Amphotericin B in the Control of Leishmania donovani Infection in India
J. Immunol., October 15, 2007; 179(8): 5592 - 5603.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
F. J. S. Rocha, U. Schleicher, J. Mattner, G. Alber, and C. Bogdan
Cytokines, Signaling Pathways, and Effector Molecules Required for the Control of Leishmania (Viannia) braziliensis in Mice
Infect. Immun., August 1, 2007; 75(8): 3823 - 3832.
[Abstract] [Full Text] [PDF]

Home page
 Infect. Immun.Home page
H. W. Murray, C. W. Tsai, J. Liu, and X. Ma
Responses to Leishmania donovani in Mice Deficient in Interleukin-12 (IL-12), IL-12/IL-23, or IL-18
Infect. Immun., July 1, 2006; 74(7): 4370 - 4374.
[Abstract] [Full Text] [PDF]